2016
Drug-Induced Hypertension in Chronic Kidney Disease
Vichot A, Perazella M. Drug-Induced Hypertension in Chronic Kidney Disease. 2016, 261-298. DOI: 10.1007/978-1-4939-6436-9_12.Peer-Reviewed Original ResearchChronic kidney diseaseCardiovascular complicationsKidney diseaseEnd-stage renal diseaseStrong risk factorHypertensive effectInflammatory syndromeBlood pressureRenal diseaseCounter medicationsMyocardial infarctionRisk factorsPhysiologic alterationsMood disordersHealthcare providersPatientsHypertensionDiseaseComplicationsMedicationsDrugsRiskPainInfarctionProviders
2008
Proton pump inhibitors: acute interstitial nephritis and other renal effects
Brewster U, Perazella M. Proton pump inhibitors: acute interstitial nephritis and other renal effects. 2008, 567-577. DOI: 10.1007/978-0-387-84843-3_25.Peer-Reviewed Original ResearchAcute interstitial nephritisProton pump inhibitorsInterstitial nephritisEnd-stage renal diseaseAnti-ulcer therapyChronic interstitial nephritisChronic interstitial diseaseDrug-drug interactionsRenal complicationsRenal effectsRenal diseasePump inhibitorsEfficacy profileInterstitial diseaseNephritisPrescribed classOmeprazoleDisease
2004
Fellows’ Forum in Dialysis. Depression: A Common but Underrecognized Condition Associated with End‐Stage Renal Disease
Perazella M, Wang P, Watnick S. Fellows’ Forum in Dialysis. Depression: A Common but Underrecognized Condition Associated with End‐Stage Renal Disease. Seminars In Dialysis 2004, 17: 237-241. PMID: 15144552, DOI: 10.1111/j.0894-0959.2004.17313.x.Peer-Reviewed Original ResearchUse of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease
Perazella M, Mosenkis A, Berns J. Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease. Seminars In Dialysis 2004, 17: 411-416. PMID: 15461751, DOI: 10.1111/j.0894-0959.2004.17351.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina, UnstableDiabetes Mellitus, Type 2Diabetic NephropathiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHeparin, Low-Molecular-WeightHumansKidney Failure, ChronicMalePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRisk AssessmentTreatment OutcomeConceptsLow molecular weight heparinIIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeEnd-stage renal diseaseMolecular weight heparinWeight heparinKidney diseaseGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsSafety of LMWHLarge prospective trialsMajor clinical trialsCardiac causesCoronary syndromeAppropriate dosingProspective trialRenal diseaseKidney functionAggressive interventionClinical benefitClinical trialsPatientsSignificant impairmentDisease
1997
Biochemical aberrations in a dialysis patient following parathyroidectomy
Cruz D, Perazella M. Biochemical aberrations in a dialysis patient following parathyroidectomy. American Journal Of Kidney Diseases 1997, 29: 759-768. PMID: 9159312, DOI: 10.1016/s0272-6386(97)90131-1.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseSevere secondary hyperparathyroidismCalcitriol therapySurgical parathyroidectomyIntensive regimenSecondary hyperparathyroidismElectrolyte abnormalitiesRenal osteodystrophySevere hypocalcemiaDialysis patientsRenal diseasePostoperative managementHigh riskParathyroidectomyPatientsBiochemical aberrationsCommon problemHyperparathyroidismHypocalcemiaHyperkalemiaHypophosphatemiaOsteodystrophyRegimenAberrationsTherapy
1996
Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance?
Cruz D, Perazella M, Abu-Alfa A, Mahnensmith R. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance? American Journal Of Kidney Diseases 1996, 28: 535-540. PMID: 8840943, DOI: 10.1016/s0272-6386(96)90464-3.Peer-Reviewed Original ResearchConceptsChronic hemodialysis patientsEnzyme inhibitor therapyACE inhibitorsHemodialysis patientsInhibitor therapySevere anemiaGroup 2Group 1End-stage renal diseaseExacerbation of anemiaSuppression of angiotensinChronic renal failureCongestive heart failureTherapy of anemiaBone marrow responseSignificant differencesRed blood cell productionRecombinant human EpoRHuEPO responseChronic hemodialysisErythropoietin resistanceRenal transplantationBaseline characteristicsHospital daysRenal failure